Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients
Status:
Completed
Trial end date:
2020-05-30
Target enrollment:
Participant gender:
Summary
Currently, no effective treatments are available for the COVID-19 pandemic, which is related
to more than 70,000 deaths all over the world. Scientists and Researchers are working on many
aspects of treatment options for the development of vaccination and medication to combat this
life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains
antibodies against COVID-19 which may be beneficial to severely sick COVID019 infected
patients. We have planned a randomized controlled trial to assess the efficacy of this
therapy in COVID-19 infected sick patients. We will collect up to 500 ml Convalescent Plasma
from the COVID-19 infected recovered patient after 14 days of clinical and radiological
recovery with two consecutive COVID-19 negative tests by PCR. We will further test the sample
from the collected plasma for COVID-19 specific antibodies and their titer. This plasma will
be frozen and sent to the treating center (MAMC). 200-600 ml of convalescent plasma will be
transfused to patients who fit the eligibility criteria and are randomized to the
convalescent plasma group. This will be done in severely sick patients. Data will be
collected for the benefit and adverse events related to convalescent plasma transfusion.